# A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02152605** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 498 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** UMEC/VI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02152605
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-01
- **Primary completion:** 2015-03-01
- **Final completion:** 2015-03-05
- **Target enrollment:** 498 (ACTUAL)
- **Last updated:** 2017-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02152605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02152605, "A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02152605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*